Impeding the Rx Market

A wide range of public and private regulations now curb cooperation among research scientists in the industry, the academy, and government.  As regards the dissemination of information about new drugs and devices, pharmaceutical companies are subject to increasingly stringent rules on the types of promotional practices that they can use to market their new products.  Together, these costly regulatory initiatives spell lower rates of innovation and slower dissemination of newer products.